C4X Discovery Holdings PLC Notice of Results (0959T)
March 18 2019 - 3:01AM
UK Regulatory
TIDMC4XD
RNS Number : 0959T
C4X Discovery Holdings PLC
18 March 2019
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Notice of Results
18 March 2019 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, will be announcing its interim
results for the six months ended 31 January 2019 on Tuesday 30
April 2019.
Clive Dix, Chief Executive Officer, and members of the
management team will host a presentation and conference call for
analysts at 12.00pm BST on the day of the results at the offices of
Panmure Gordon, 1 New Change, London, EC4M 9AF. Presentation slides
for the analyst call will be made available on the Company website
in advance of the call at www.c4xdiscovery.com.
-ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer +44 (0)7801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance) +44 (0)20 7886
2500
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards the pre-clinical licensing
discussions. In selecting new targets and executing new drug
discovery programmes, C4X Discovery focuses on high-value disease
areas that are the subject of significant licensing activity and
will continue to also maximise value from opportunistic areas such
as addiction and diabetes. The Company recently signed a licensing
agreement with Indivior for a pre-clinical addiction programme
worth up to $294 million.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORJRMBTMBMBTTL
(END) Dow Jones Newswires
March 18, 2019 03:01 ET (07:01 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024